Results 281 to 290 of about 4,079,288 (357)
TTT and R2TP chaperone complexes are required for the assembly and activation of mTORC1. WAC directly interacts with components of TTT, R2TP, and mTORC1, and these interactions are affected by the availability of glucose and glutamine, correlating with changes in mTORC1 activity.
Sofía Cabezudo+11 more
wiley +1 more source
Theranostic Near-Infrared Monoamine Oxidase Inhibitor (NMI) Protein Binding Interactions with MAOA and Albumin. [PDF]
Irwin RW+4 more
europepmc +1 more source
Nitric oxide‐forming nitrite reductases in the anaerobic ammonium oxidizer Kuenenia stuttgartiensis
Anammox bacteria remove fixed nitrogen from their environment via anaerobic ammonium oxidation (anammox) with nitrite as electron acceptor and dinitrogen gas as product. The first anammox step is the conversion of nitrite to nitric oxide by nitrite reductase.
Femke J. Vermeir+4 more
wiley +1 more source
Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG. [PDF]
Bellier JP+15 more
europepmc +1 more source
Two‐way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3
PAX5::CBFA2T3 (PAX5‐C) is a fusion protein of the B‐cell transcription factor, PAX5, and is found in B‐cell ALL. We propose a putative model of two‐way inhibition of PAX5 transcriptional activity by PAX5‐C. There are two ways of repression by PAX5‐C: DNA‐binding‐dependent way and HDAC‐dependent way, with either being sufficient for the repression. HDAC
Reina Ueno+12 more
wiley +1 more source
Non-linear plasma protein binding of cannabidiol. [PDF]
Babayeva M, Srdanovic I.
europepmc +1 more source
Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu+12 more
wiley +1 more source
Generating and validating renewable affimer protein binding reagents targeting SH2 domains. [PDF]
Heseltine SJ+11 more
europepmc +1 more source